VVM
TPST icon

Versant Venture Management’s Tempest Therapeutics TPST Stock Holding History

Versant Venture Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Hold
269,772
– – 0.18% 8
2026
Q1 		$442K Hold
269,772
– – 0.31% 8
2025
Q4 		$774K Hold
269,772
– – 0.51% 7
2025
Q3 		$2.77M Hold
269,772
– – 1.31% 8
2025
Q2 		$1.83M Sell
269,772
-1
-0% -$7 2.23% 7
2025
Q1 		$2.59M Hold
269,773
– – 4.3% 6
2024
Q4 		$2.93M Buy
+269,773
New +$3.48M 3.37% 6

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Versant Venture Management's TPST Position: Q2 2026 in Review

Versant Venture Management held its Tempest Therapeutics (TPST) position steady in Q2 2026 at 269,772 shares worth $299K. The position accounts for 0.18% of the portfolio, ranked #8.

Versant Venture Management first reported a position in TPST in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.93M in Q4 2024. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Versant Venture Management held 269,772 shares of Tempest Therapeutics worth $299K as of Q2 2026.
  • Versant Venture Management left its Tempest Therapeutics share count unchanged in Q2 2026.
  • Tempest Therapeutics made up 0.18% of Versant Venture Management's portfolio in Q2 2026, its #8 holding.
  • Versant Venture Management first reported a position in Tempest Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Versant Venture Management's Tempest Therapeutics position peaked at $2.93M in Q4 2024.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Versant Venture Management's 13F filing for Q2 2026, filed 12 Aug 2026.